Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alex Shimmings

Alexandra has more than 20 years' experience covering pharmaceutical and biotech R&D. An early interest in medicine, and a dawning realization that being a doctor was not for her, led to a degree in Biochemistry and Microbiology at the University of Leeds, and a move to London to pursue a career in medical journalism. Now Scrip's Managing Editor, Alex has held a variety of roles on the publication since starting as a science reporter in 1998. She instigated some of Scrip's signature features, such as the Pipeline Watch and New Active Substance lists, and also casts an editorial eye over the annual Scrip Awards. Alex's main work interests lie in novel drugs and pharmaceutical and biotech R&D, and she also enjoys medical history and current affairs.

Latest From Alex Shimmings

Novavax’s COVID-19 Vaccine Boost From First Phase I Data

A first look at the clinical data for Novavax’s COVID-19 vaccine suggests it can produce strong antibody responses while being well tolerated.

Companies Coronavirus COVID-19

Acadia Hit By Two Surprise Disappointments With Nuplazid

A couple of unexpected events for pimavanserin mean that Acadia will drop its development for major depressive disorder and have to wait a little longer to hear if it can launch the product for dementia-related psychosis, a large potential indication.

Clinical Trials Companies

US Approval For ViiV’s ‘Last Resort’ HIV Drug Rukobia

The US FDA has given the go-ahead for marketing of ViiV healthcare’s novel HIV drug just as the EMA removes the accelerated assessment status from its application there.

Approvals Infectious Diseases

Executives On The Move: BioXcel Therapeutics Picks A Development Officer, A Finance Hire At RenovaCare And CANbridge Taps Takeda Talent

Immuno-oncology and neuroscience firm BioXcel Therapeutics picks a chief development officer, and stem-cell therapy company RenovaCare hires a CFO. Plus, CANbridge Life Sciences, developer of specialty health products, adds Takeda Pharma rare disease lead as global head, business development.

Appointments BioPharmaceutical

Genmab And Seattle Genetics Progress Cervical Cancer ADC

Topline Phase II data for the antibody-drug conjugate tisotumab vedotin put it on a swift path towards approval in cervical cancer.

Clinical Trials Companies

Sanofi Confirms Up To 1,680 Job Losses In Europe

The layoffs are part of its bid to cut costs outlined in December.

Companies Commercial
See All
UsernamePublicRestriction

Register